Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients

1994 ◽  
Vol 151 (1) ◽  
pp. 35-39 ◽  
Keyword(s):  
Side Effects ◽  
Treatment Response ◽  
First Episode ◽  
Extrapyramidal Side Effects ◽  
Schizophrenic Patients

Neuroleptic Prescription for Chinese Schizophrenics in Hong Kong

1992 ◽  
Vol 26 (2) ◽  
pp. 262-264 ◽  
Author(s):  
Helen Chiu ◽  
Sing Lee ◽  
C.M. Leung ◽  
Y.K. Wing
Keyword(s):  
Hong Kong ◽  
Side Effects ◽  
High Frequency ◽  
Anticholinergic Drugs ◽  
Extrapyramidal Side Effects ◽  
High Potency ◽  
Frequency Of Use ◽  
Daily Dose ◽  
Schizophrenic Patients ◽  
The Mean

There are very few studies on the pattern of neuroleptic prescription for schizophrenics in Asia. 106 schizophrenic patients in a psychiatric unit of a general teaching hospital in Hong Kong were surveyed. The mean daily dose (in chlorpromazine equivalent) was low (568.5mg). The mean daily dose of high potency agents was four times that of low potency agents. A high frequency of use of anticholinergic drugs may indicate that Chinese are more susceptible to acute extrapyramidal side-effects.

Sulpiride: an advance in neuroleptics?

1984 ◽  
Vol 22 (8) ◽  
pp. 31-32
Keyword(s):  
Side Effects ◽  
Social Withdrawal ◽  
Extrapyramidal Side Effects ◽  
Schizophrenic Patients ◽  
Substituted Benzamide ◽  
The Uk

Sulpiride (Dolmatil - Squibb) is a substituted benzamide related to metoclopramide. It has only recently been marketed in the UK, but has been used in Europe for many years. The manufacturer claims that the drug has both antidepressive and neuroleptic properties, and that it is of particular benefit for schizophrenic patients who develop social withdrawal. Extrapyramidal side effects are claimed to be less than with conventional neuroleptics.

scholarly journals Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis

2010 ◽  
Vol 196 (6) ◽  
pp. 434-439 ◽  
Author(s):  
Nicolas A. Crossley ◽  
Miguel Constante ◽  
Philip McGuire ◽  
Paddy Power
Keyword(s):  
Side Effects ◽  
Randomised Controlled Trials ◽  
Atypical Antipsychotics ◽  
Meta Analysis ◽  
Evidence Base ◽  
First Episode ◽  
Controlled Trials ◽  
Extrapyramidal Side Effects ◽  
Randomised Controlled ◽  
Typical Antipsychotics

BackgroundThere is an ongoing debate about the use of atypical antipsychotics as a first-line treatment for first-episode psychosis.AimsTo examine the evidence base for this recommendation.MethodMeta-analyses of randomised controlled trials in the early phase of psychosis, looking at long-term discontinuation rates, short-term symptom changes, weight gain and extrapyramidal side-effects. Trials were identified using a combination of electronic (Cochrane Central, EMBASE, MEDLINE and PsycINFO) and manual searches.ResultsFifteen randomised controlled trials with a total of 2522 participants were included. No significant differences between atypical and typical drugs were found for discontinuation rates (odds ratio (OR) = 0.7, 95% CI 0.4 to 1.2) or effect on symptoms (standardised mean difference (SMD) = –0.1, 95% CI –0.2 to 0.02). Participants on atypical antipsychotics gained 2.1 kg (95% CI 0.1 to 4.1) more weight than those on typicals, whereas those on typicals experienced more extrapyramidal side-effects (SMD = –0.4, 95% CI –0.5 to –0.2).ConclusionsThere was no evidence for differences in efficacy between atypical and typical antipsychotics, but there was a clear difference in the side-effect profile.

Biperiden and Haloperidol Plasma Levels and Extrapyramidal Side Effects in Schizophrenic Patients

1997 ◽  
Vol 36 (2) ◽  
pp. 69-72 ◽  
Author(s):  
Kurt Meszaros ◽  
Elisabeth Lenzinger ◽  
Kurt Hornik ◽  
Georg Schönbeck ◽  
Reinhold Hatzinger ◽  
...  
Keyword(s):  
Side Effects ◽  
Plasma Levels ◽  
Extrapyramidal Side Effects ◽  
Schizophrenic Patients

Relapse prevention in schizophrenia: attitudes of neurologists-psychiatrists

2001 ◽  
Vol 16 (2) ◽  
pp. 90-98 ◽  
Author(s):  
J.D. Bergiannaki ◽  
J. Hatzimanolis ◽  
J. Liappas ◽  
P.N. Sakkas ◽  
C.N. Stefanis
Keyword(s):  
Side Effects ◽  
Mental Health Professionals ◽  
Treatment Strategies ◽  
Treatment Compliance ◽  
International Standards ◽  
First Episode ◽  
Treatment And Prevention ◽  
Schizophrenic Patients ◽  
Prevention Of Relapse ◽  
Relapse Rates

The overall high relapse rates observed in schizophrenia are attributed to several causes. One important factor influencing satisfactory prevention of relapse is the lack of consistent treatment strategies among medical doctors, especially neurologists-psychiatrists. Nearly one-third of the members of the Hellenic Society of Neurology and Psychiatry were asked to fill in anonymously a structured questionnaire on their treatment attitudes and prescribing tactics regarding schizophrenic patients both after the first schizophrenic episode and after multiple episodes. The majority of Greek neurologists-psychiatrists seem to adopt prescribing habits that approximate the current international standards for prevention of schizophrenic relapse. Their attitudes regarding the treatment and prevention of relapse for the first schizophrenic episode and first relapse are determined from multiple factors. These are: the expected relapse rates after the first episode, the expected prevalence of extrapyramidal side effects following a long-term neuroleptic treatment, the patient’s expected treatment compliance after the first episode, the doctor’s experience with treating schizophrenics, and lastly the knowledge of current literature on the topic. These results point to the need for continuing education, especially of the younger mental health professionals and those working in the private sector, addressing the issue of the actual risk of developing side effects from the treatment. In due course, benefits could result for everyday psychiatric practice and the patients’ compliance with treatment.

Quetiapine in relapsing schizophrenia: clinical efficacy and effect on monoaminergic parameters

2003 ◽  
Vol 15 (3) ◽  
pp. 133-139 ◽  
Author(s):  
F. M. M. A. van der Heijden ◽  
W. M. A. Verhoeven ◽  
D. Fekkes ◽  
A. E. S. Sijben ◽  
S. Tuinier
Keyword(s):  
Side Effects ◽  
Treatment Effect ◽  
Biochemical Parameters ◽  
Controlled Trial ◽  
Response To Treatment ◽  
Extrapyramidal Side Effects ◽  
Open Label ◽  
Schizophrenic Patients ◽  
Efficacy Measures ◽  
Efficacy Parameters

Methods:Tolerability, safety and effectiveness of quetiapine in an in-patient group with a relapse of schizophrenia and the possible role of plasma amino acid concentrations, 5-HT parameters and HVA in the prediction of response to treatment were investigated in an open-label baseline-controlled trial of 14 weeks in 21 hospitalized schizophrenic patients. Responders were defined as those patients who exhibit at least a 40% reduction of BPRS total scores. Secondary efficacy measures were the PANSS, the Clinical Global Impression (CGI)-severity scale and the MADRS. Extrapyramidal side-effects were evaluated with the AIMS. Other side-effects were monitored at regular intervals. Amino acids and the derived tryptophan and tyrosine ratios, as well as monoaminergic parameters, were assessed in plasma at baseline and at weeks 3, 6 and 14.Results:Treatment with quetiapine resulted in the predefined treatment effect in 10 out of the 17 patients who completed at least 4 weeks of treatment. Effect in responders was observed on all efficacy parameters, including lower MADRS scores. No extrapyramidal side-effects emerged. Clinical and biochemical parameters did not predict response to treatment.Conclusions:This study demonstrates the moderate antipsychotic efficacy of quetiapine on preferentially positive symptoms in a group of relatively young schizophrenics. Some observed changes in biochemical parameters are discussed.

Sign in / Sign up

Export Citation Format

Share Document